LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$4.93
+1.86%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
Market Cap
$404.49M
MomentumView details →
1D Return
+1.86%
YTD Return
−50.81%
RSI (14)
51.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
Market Cap
$404.49M
RSI (14)
51.8
MomentumView details →
1D Return
+1.86%
YTD Return
−50.81%
SummaryUpdated Jun 1, 2026
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company founded in 2017 and headquartered in New York, New York. The company went public in November 2023 and focuses on developing gene therapies for both hereditary and acquired diseases. Lexeo operates in the biotechnology sector, specifically targeting genetic disorders through advanced gene therapy approaches using adeno-associated virus (AAV) vectors.
Similar companies
Latest newsMore news →
Lexeo Therapeutics reported its Q2 2026 financial results, with a net loss of $25.9 million and diluted EPS of -$0.30, and cash, cash equivalents and investments of $234.2 million as of June 30, 2026.24d agoThe FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lexeo Therapeutics for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy, based on interim clinical data from an ongoing Phase I/II trial.30d ago